Olink Breakfast Symposium: From Discovery to Quantified Cytokines: Actionable Insights on the Low Abundant Plasma Proteome

Description:

The study of inflammation as a vital process in the body’s immunological response to infection in injury contributes significantly to understanding pathophysiology of many human diseases. The COVID-19 pandemic emphasized the disastrous potential of inflammatory molecules, where “cytokine release storms” resulting from excessive immune responses to the virus were responsible for severe or fatal disease in some patients.

This presentation will cover the underlying Olink technology to interrogate 45 protein biomarkers from only a single microliter of biological sample (either in standard concentration units or in relative normalized units).

The applications of this highly multiplexed immunoassay will cover the study of inflammation, whether well-studied autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, or common disease such as cardiovascular disease, neurological disorders and cancer.

Speaker biography:

Dale Yuzuki, M.A., M.Ed. currently is a Digital Strategic Marketing Communications Director at Olink Proteomics, where he drives strategic messaging and content development across Olink’s digital communications channels. He has a background in regional marketing, product management and different sales roles since 23 years, and is the author of a popular NGS blog “The Next Generation Technologist” www.yuzuki.org since 2011. In 2014/15 he launched the “Behind the Bench blog” at Thermo Fisher Scientific and produced several dozen video interviews and over 100 blog posts on that platform. Before joining Olink a year ago he authored a book on the molecular biology behind COVID diagnostics, therapeutics and vaccines, called “COVID-19: From Chaos To Cure: The biology behind the fight against the novel coronavirus”.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden. Learn more about Olink here.